Endocrine Abstracts

Introduction: Recently, Programmed cell death ligand 1 (PD-L1) inhibitors have been frequently used as promising treatment options for some advanced malignancies. Although immune-related side effects secondary to PD-1 inhibitor treatment are well defined in the literature, data on PD-L1 inhibitors are limited. Thyroid dysfunction was reported in 10% of patients in the clinical study of atezolizumab. We aimed to present a case of severe hypothyroidism-related rhabdomyolysis and...

Introduction: Atypical parathyroid tumour (APT) is a rare cause of primary hyperparathyroidism (PHPT) with a frequency of 1.2-1.3%. APT is a lesion with suspicious clinical and histological features of malignancy which does not completely respect the World Health Organization (WHO) criteria for diagnosis of Parathyroid Carcinoma (PC). There is a well-known association with PHT and medullary thyroid carcinoma for multiple endocrine neoplasia. However, concurrence of thyroid pap...